

Supplemental Table 1. Identification of factors associated with response to tetracyclines

	HiSCR			MCID DLQI			MCID NRS Pain		
	n	OR (95% CI)	p-value	n	OR (95% CI)	p-value	n	OR (95% CI)	p-value
<u>Patient characteristics</u>									
Gender*	137	0.83 (0.41-1.67)	0.600	160	0.64 (0.33-1.25)	0.191	97	1.01 (0.44-2.36)	0.975
Age	137	1.02 (0.99-1.04)	0.260	160	1.02 (0.99-1.04)	0.207	97	1.04 (1.01-1.08)	0.024
Age of onset	135	1.02 (0.98-1.05)	0.384	157	1.00 (0.97-1.04)	0.790	96	1.05 (1.00-1.12)	0.037
Disease duration	135	1.02 (0.98-1.06)	0.453	157	1.03 (0.99-1.06)	0.120	96	1.01 (0.97-1.06)	0.539
BMI	132	0.99 (0.93-1.05)	0.625	154	1.00 (0.94-1.05)	0.865	93	0.95 (0.88-1.03)	0.223
Smoking status*	137	1.21 (0.60-2.47)	0.595	160	1.05 (0.54-2.04)	0.895	96	2.22 (0.96-5.17)	0.064
Family history of HS*	130	0.84 (0.40-1.78)	0.648	150	1.53 (0.76-3.06)	0.234	89	1.30 (0.54-3.16)	0.559
Previous surgical treatment*	137	1.39 (0.69-2.80)	0.363	160	1.09 (0.57-2.11)	0.788	97	2.53 (1.02-6.26)	0.046
<u>Patient reported outcome measures at baseline</u>									
DLQI	132	1.03 (0.98-1.08)	0.241	160	1.07 (1.02-1.13)	0.003	94	1.01 (0.95-1.07)	0.715
NRS Pain	133	1.05 (0.92-1.20)	0.430	157	1.06 (0.94-1.19)	0.358	96	1.00 (0.83-1.20)	0.960
NRS Pruritus	129	1.10 (0.98-1.23)	0.121	152	1.14 (1.02-1.26)	0.022	93	1.06 (0.92-1.22)	0.389
<u>Physician scores at baseline</u>									
Inflammatory nodule count	137	1.08 (0.99-1.17)	0.098	160	1.05 (0.97-1.13)	0.245	97	1.15 (1.02-1.30)	0.023
Abscess count	137	0.94 (0.81-1.08)	0.369	160	0.96 (0.83-1.11)	0.570	97	1.10 (0.92-1.33)	0.303
Draining sinus tract count	137	0.95 (0.84-1.08)	0.428	160	0.91 (0.80-1.03)	0.135	97	1.14 (0.95-1.37)	0.159
Presence of sinus tracts	137	0.76 (0.38-1.50)	0.421	160	0.80 (0.42-1.54)	0.510	97	1.91 (0.84-4.35)	0.124
<u>Hurley stage</u>									
Hurley stage I		reference			reference			reference	
Hurley stage II	137	1.14 (0.58-2.27)	0.702	159	0.92 (0.48-1.75)	0.788	97	1.44 (0.63-3.26)	0.386
Hurley stage III	137	0.85 (0.36-2.03)	0.713	159	0.75 (0.33-1.71)	0.493	97	2.59 (0.86-7.79)	0.090
IHS4	137	1.00 (0.97-1.02)	0.662	160	0.99 (0.97-1.01)	0.268	97	1.04 (1.00-1.08)	0.041
Mild		reference			reference			reference	
Moderate	137	0.66 (0.33-1.33)	0.248	160	1.08 (0.56-2.08)	0.812	97	0.57 (0.25-1.31)	0.185
Severe	137	1.46 (0.74-2.90)	0.280	160	0.86 (0.45-1.65)	0.649	97	4.17 (1.73-10.00)	0.001
Modified Sartorius	109	0.98 (0.97-1.00)	0.059	128	0.98 (0.97-1.00)	0.059	76	1.00 (0.98-1.02)	0.765

OR; Odds ratio, MCID; minimal clinically important difference, DLQI; Dermatology Quality of Life Index, NRS; Numerical rating scale, BMI; body mass index, IHS4; International Hidradenitis Suppurativa Scoring System. * reference categories; female, non-smokers, no family history, no previous surgical treatment

Supplemental Table 2. Identification of factors associated with response to clindamycin and rifampicin

	HiSCR			MCID DLQI			MCID NRS Pain		
	n	OR (95% CI)	p-value	n	OR (95% CI)	p-value	n	OR (95% CI)	p-value
<u>Patient characteristics</u>									
Gender*	83	1.39 (0.58-3.30)	0.458	93	1.74 (0.76-3.96)	0.187	80	0.88 (0.35-2.19)	0.784
Age	82	1.03 (1.00-1.07)	0.095	92	0.99 (0.96-1.03)	0.706	80	1.01 (0.97-1.04)	0.645
Age of onset	83	1.04 (0.99-1.08)	0.131	93	1.00 (0.96-1.04)	0.982	80	1.01 (0.97-1.06)	0.558
Disease duration	82	1.01 (0.97-1.06)	0.526	92	1.00 (0.96-1.04)	0.936	80	1.00 (0.96-1.03)	0.814
BMI	83	1.01 (0.94-1.09)	0.769	93	1.00 (0.93-1.07)	0.957	80	1.04 (0.96-1.12)	0.333
Smoking status*	81	1.65 (0.67-4.07)	0.275	90	2.14 (0.91-5.06)	0.082	78	1.84 (0.73-4.68)	0.197
Family history of HS*	78	1.32 (0.52-3.30)	0.560	88	0.58 (0.24-1.40)	0.227	76	0.99 (0.37-2.61)	0.979
Previous surgical treatment*	82	0.80 (0.33-1.92)	0.617	91	1.42 (0.61-3.30)	0.411	78	0.97 (0.38-2.46)	0.941
<u>Patient reported outcome measures at baseline</u>									
DLQI	79	1.04 (0.98-1.10)	0.166	91	1.19 (1.10-1.30)	<0.001	76	1.03 (0.97-1.10)	0.322
NRS Pain	83	0.95 (0.79-1.13)	0.553	93	1.03 (0.87-1.22)	0.710	80	1.03 (0.83-1.28)	0.814
NRS Pruritus	79	1.02 (0.90-1.16)	0.714	88	1.07 (0.95-1.20)	0.272	76	1.08 (0.94-1.24)	0.259
<u>Physician scores at baseline</u>									
Inflammatory nodule count	83	1.04 (0.96-1.12)	0.335	93	1.00 (0.93-1.07)	0.930	80	1.11 (1.01-1.23)	0.034
Abscess count	83	0.99 (0.85-1.16)	0.925	93	1.21 (1.01-1.45)	0.035	80	1.31 (0.01-1.69)	0.040
Draining sinus tract count	83	0.96 (0.86-1.07)	0.409	93	0.90 (0.78-1.04)	0.140	80	0.99 (0.85-1.16)	0.929
Presence of sinus tracts	83	1.02 (0.39-2.67)	0.967	93	0.55 (0.21-1.41)	0.212	80	0.76 (0.27-2.17)	0.612
Hurley stage									
Hurley stage I		reference			reference			reference	
Hurley stage II	83	1.30 (0.55-3.12)	0.550	93	1.16 (0.51-2.64)	0.716	80	0.86 (0.34-2.16)	0.747
Hurley stage III	83	0.90 (0.36-2.24)	0.819	93	0.72 (0.30-1.72)	0.463	80	1.21 (0.46-3.21)	0.699
IHS4	83	1.00 (0.98-1.02)	0.649	93	0.99 (0.96-1.01)	0.481	80	1.02 (0.99-1.05)	0.183
Mild		reference			reference			reference	
Moderate	83	0.99 (0.39-2.53)	0.982	93	0.98 (0.42-2.29)	0.970	80	0.71 (0.28-1.82)	0.472
Severe	83	1.23 (0.50-3.04)	0.653	93	1.18 (0.52-2.68)	0.698	80	1.81 (0.72-4.54)	0.210
Modified Sartorius	52	1.00 (0.97-1.12)	0.622	55	0.99 (0.97-1.01)	0.167	46	0.99 (0.97-1.01)	0.527

OR; Odds ratio, MCID; minimal clinically important difference, DLQI; Dermatology Quality of Life Index, NRS; Numerical rating scale, BMI; body mass index, IHS4; International Hidradenitis Suppurativa Scoring System. * reference categories; female, non-smokers, no family history, no previous surgical treatment